CellCarta and Waters Corporation Formed Diagnostic Partnership
The two companies joined forces to provide standardized flow cytometry platforms and clinical laboratory support.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that deeper corporate collaboration in drug development will improve patient outcomes?
CellCarta and Waters Corporation have entered a strategic partnership to support companion diagnostics and flow cytometry development for clinical trials. The collaboration aims to provide pharmaceutical and biotechnology sponsors with integrated laboratory services and standardized platforms from Phase I through Phase III.
Why it matters
The partnership seeks to simplify complex clinical programs and maintain continuity for biopharmaceutical sponsors conducting global research. By leveraging standardized technology, the companies aim to facilitate the inclusion of sites like Jining, China, into multinational biomarker studies.
The partnership focuses on standardizing flow cytometry platforms, software analysis tools, and reagent use for clinical trials ranging from Phase I to Phase III. CellCarta will deploy these validated assays through its global CDx Lab Network to ensure consistency.
The players
CellCarta
This global provider of precision medicine laboratory services specializes in biomarker research and companion diagnostics.
Waters Corporation
This analytical laboratory instrument and software company focuses on mass spectrometry, thermal analysis, and flow cytometry technologies.
The details
Waters Corporation contributes instrumentation, reagents, and standardized panels, while CellCarta offers biomarker research, regulatory support, and clinical development expertise. The collaboration allows sponsors to utilize CellCarta's CAP-accredited laboratory in Jining, China, alongside other global facilities to generate unified clinical evidence.
Timeline
The strategic partnership was officially announced on October 13, 2026.
The Tech Race
This partnership reflects a broader industry movement toward standardizing complex analytical workflows to solve the problem of data heterogeneity in global clinical research. By replacing siloed, non-standardized testing methods, the firms position themselves to better compete for large-scale multinational drug development contracts.
For pharmaceutical and biotech sponsors, this integration offers a more efficient path to regulatory approval by minimizing site-specific technical discrepancies. The standardization of assays means researchers can more easily manage trials across international borders, including in previously hard-to-integrate markets like China.
The takeaway
This collaboration highlights the growing importance of infrastructure-level standardization in the rapidly expanding field of companion diagnostics. Organizations that consolidate analytical platforms can better navigate the regulatory complexities of modern global drug development.
Further reading
Learn more about the latest industry developments at Biotech.
Source note: This article includes information reported by Selectscience.
Live Poll
Do you trust that deeper corporate collaboration in drug development will improve patient outcomes?
